Cholesterol Uptake Capacity: A New Measure of HDL Functionality for Coronary Risk Assessment

Area of Science:

• Biochemistry
• Cardiovascular Science
• Clinical Diagnostics

Background:

• High-density lipoprotein (HDL) cholesterol efflux capacity is a superior cardiovascular disease (CVD) predictor compared to HDL cholesterol levels.
• Current methods for measuring HDL functionality rely on radioisotopes and cell cultures, limiting clinical applicability.
• A need exists for a simpler, more accessible assay to assess HDL function in clinical settings.

Purpose of the Study:

• To develop and validate a novel cell-free assay for measuring HDL cholesterol uptake capacity.
• To assess the utility of this assay in patients with coronary artery disease (CAD).

Main Methods:

• A cell-free system using fluorescently labeled cholesterol and an anti-apolipoprotein A1 antibody was developed to measure cholesterol uptake capacity.
• The assay was applied to serum samples from patients with CAD who had undergone revascularization.
• Cholesterol uptake capacity was correlated with cholesterol efflux capacity and clinical outcomes.

Main Results:

• The cholesterol uptake capacity assay demonstrated high reproducibility (CV <10%) and a rapid processing time (<6 hours).
• Myeloperoxidase-mediated oxidation of serum impaired cholesterol uptake capacity.
• Cholesterol uptake capacity correlated significantly with cholesterol efflux capacity (r² = 0.47) and inversely with revascularization events in patients with controlled LDL cholesterol.
• Multivariate analysis confirmed cholesterol uptake capacity as an independent predictor of CVD risk (OR, 0.48; P = 0.0048).

Conclusions:

• The cholesterol uptake capacity assay provides a sensitive, high-throughput, and cell-free method for evaluating HDL functionality.
• This assay does not require radioisotopes or cell cultures, facilitating clinical application.
• Cholesterol uptake capacity assay is a promising tool for assessing CVD risk in clinical settings.